免疫抑制治疗对快速进展性继发性IgA肾病肾脏及患者生存的影响
经倾向性评分逆概率加权及界标分析校正后,治疗升级与肾脏衰竭进展或全因死亡均无显著关联。肝病是最常见的基础疾病,且与最差的肾脏生存相关。
要点
- 快速进展性继发性IgA肾病肾脏预后和患者生存均较差。
- 治疗升级(激素基础上加用免疫抑制)未改善肾脏或患者生存。
- 肝病相关IgA肾病及就诊时透析独立预测肾脏衰竭。
核心结论
- 在快速进展性继发性IgA肾病患者中,校正基线严重程度、竞争风险和永恒时间偏倚后,治疗升级与肾脏生存或患者生存改善无关。
研究设计与样本
- 患者接受单纯支持治疗、支持治疗加糖皮质激素、或糖皮质激素联合其他免疫抑制治疗。
- 采用基于倾向性评分的逆概率治疗加权校正适应证混杂,治疗升级定义为超出糖皮质激素的免疫抑制治疗。
- 采用界标分析(主要30天,敏感性14天)减少永恒时间偏倚。
- 主要结局为肾脏衰竭,以死亡作为竞争事件;全因死亡率采用加权Cox模型评估。
主要发现
- 肝病是最常见的基础疾病(51%);中位随访36个月期间,32例(35%)发生肾脏衰竭,34例(37%)死亡。
- 加权后基线协变量均衡;治疗升级与肾脏衰竭进展无关联(30天界标:SHR 1.09,95%CI 0.35-3.38;14天界标:SHR 1.40,95%CI 0.49-4.03)。
- 治疗升级与全因死亡无关联(30天:HR 1.20,95%CI 0.34-4.17;14天:HR 1.14,95%CI 0.32-4.08)。
- 肾脏生存因病因不同而异(log-rank P = 0.006),肝病相关IgA肾病结局最差;肝病(HR 3.16,95%CI 1.07-9.33)和就诊时透析(HR 4.20,95%CI 1.44-12.28)独立预测肾脏衰竭。
临床怎么用
- 对于快速进展性继发性IgA肾病患者,在支持治疗基础上加用免疫抑制治疗可能不能改善肾脏或患者生存。
- 肝病相关IgA肾病及就诊时即需透析的患者肾脏预后尤其差,应加强监测与支持治疗。
局限性
- 回顾性观察性设计,尽管采用倾向性评分加权和界标分析,仍可能存在未测量混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secondary IgA nephropathy (IgAN) associated with systemic diseases represents a heterogeneous population in whom renal prognosis and treatment response are poorly defined. Patients with secondary IgAN have been excluded from major trials, and the benefit of adding immunosuppressive therapy to supportive care remains uncertain. METHODS: We conducted a retrospective multicenter cohort study including adults with biopsy-proven rapidly progressive secondary IgAN. Patients received supportive care alone, supportive care plus corticosteroids, or corticosteroids with additional immunosuppression. To address confounding by indication, inverse probability of treatment weighting based on propensity scores was applied, defining treatment escalation as immunosuppressive therapy beyond corticosteroids. Exposure was defined using landmark analyses (primary 30-day; sensitivity 14-day) to reduce immortal time bias. The primary outcome was kidney failure, accounting for death as a competing event. All-cause mortality was assessed using weighted Cox models. RESULTS: Ninety-two patients were included (mean age 61 ± 16 years; 83% male). Mean eGFR at presentation was 17±10 mL/min/1.73 m², and 32% required dialysis. Liver disease was the most frequent underlying condition (51%). Over a median follow-up of 36 months, 32 patients (35%) developed kidney failure and 34 (37%) died. After weighting, baseline covariates were balanced. Treatment escalation was not associated with progression to kidney failure (30-day landmark: subdistribution hazard ratio [SHR] 1.09, 95% confidence interval [CI] 0.35-3.38; 14-day landmark: SHR 1.40, 95% CI 0.49-4.03) or all-cause mortality (30-day: hazard ratio [HR] 1.20, 95% CI 0.34-4.17; 14-day: HR 1.14, 95% CI 0.32-4.08). Renal survival differed by etiology (log-rank P = 0.006), with the poorest outcomes in liver disease-associated IgAN. Liver disease (HR 3.16, 95% CI 1.07-9.33) and dialysis at presentation (HR 4.20, 95% CI 1.44-12.28) independently predicted kidney failure. CONCLUSION: Rapidly progressive secondary IgAN carries high renal and patient mortality. After accounting for baseline severity, competing risk, and immortal time bias, treatment escalation was not associated with improved renal or patient survival.
引用
- Shabaka A, Sevillano ÁM, Vian J, et al. Impact of immunosuppressive therapy on renal and patient survival in rapidly progressive secondary IgA nephropathy. Nephrol Dial Transplant. 2026. PMID: 42409357. doi:10.1093/ndt/gfag158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。